[Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005111
Original Title: (177Lu)Lutetiumvipivotidtetraxetan (Prostatakarzinom) - Addendum zum Projekt A23-01 (Dossierbewertung)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Prostatic Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Lutetium
  • Antineoplastic Agents
  • Radiopharmaceuticals
  • 177Lu-PSMA-617
  • Prostatic Neoplasms - Castration-Resistant
  • Benefit Assessment
  • NCT03511664
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: <p>Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.